Skip to content

PTC Therapeutics PTCT Change in Deferred Revenue

Change in Deferred Revenue at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$2.38M+7.5%
Arrowhead Research logo
Arrowhead ResearchARWR
$163.36M
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$99.6M+463%
Cytokinetics logo
CytokineticsCYTK
$41K
ALN
Alnylam PharmaceuticalsALNY
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$6.55B+40.3%
Enterprise value$6.11B+77.3%
P/E
P/S7.9×+5.3×

Profitability

See full
Gross margin96%
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%
Debt / equity372.3×
Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's change in deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTC Therapeutics's change in deferred revenue?
PTC Therapeutics (PTCT) reported change in deferred revenue of -$1.52M in Q1 2026.
How has PTC Therapeutics's change in deferred revenue changed year-over-year?
PTC Therapeutics's change in deferred revenue decreased by 121.1% year-over-year, from $7.2M to -$1.52M.
What does change in deferred revenue mean?
Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.